Identifying optimal initial infusion rates for unfractionated heparin in morbidly obese patients

Annals of Pharmacotherapy

Volumn 44, Issue 7-8, 2010, Pages 1141-1151

  Riney, Jennifer N ^a   Hollands, James M ^a   Smith, Jennifer R ^a   Deal, Eli N ^a  

^a BARNES JEWISH HOSPITAL   (United States)

Author keywords

Anticoagulation; BMI; Body mass index; Heparin; Nomogram; Obesity; Unfractionated heparin

Indexed keywords

HEPARIN; ANTICOAGULANT AGENT;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLEEDING; BODY MASS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; INFUSION RATE; MAJOR CLINICAL STUDY; MALE; MORBID OBESITY; MORTALITY; NOMOGRAM; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; VENOUS THROMBOEMBOLISM; BODY WEIGHT; CHEMICALLY INDUCED; COHORT ANALYSIS; COMPLICATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; OBESITY; PROSPECTIVE STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BODY WEIGHT; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMORRHAGE; HEPARIN; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NOMOGRAMS; OBESITY; OBESITY, MORBID; PARTIAL THROMBOPLASTIN TIME; PROSPECTIVE STUDIES;

EID: 77954575145     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P088     Document Type: Article

References (34)

1. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among U.S. adults, 1999-2008. JAMA 2010;303:235-41. DOI 10.1001/jama.2009.2014
2. Wang Y, Beydoun MA. The obesity epidemic in the United States - gender, age, socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and meta-regression analysis. Epidemiol Rev 2007; 29:6-28. DOI 10.1093/epirev/mxm007 (Pubitemid 47229643)
3. Cipolle RJ, Seifert RD, Neilan BA, Zaske DE, Haus E. Heparin kinetics: variables related to disposition and dosage. Clin Pharmacol Ther 1981; 29:387-93.
4. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. Ann Intern Med 1993;119:874-81.
5. Shalansky KF, FitzGerald JM, Sunderji R, et al. Comparison of a weight-based heparin nomogram with traditional heparin dosing to achieve therapeutic anticoagulation. Pharmacotherapy 1996;16:1076-84. (Pubitemid 26403650)
6. Yee WP, Norton LL. Optimal weight base for a weight-based heparin dosing protocol. Am J Health Syst Pharm 1998;55:159-62.
7. Pinder T, Daughtry W, Shah Z, et al. A weight-based heparin protocol for improved anticoagulation in a coronary care unit. J Clin Outcomes Manage 1999;6(5):27-33.
8. Spruill WJ, Wade WE, Huckaby WG, Leslie RB. Achievement of anticoagulation by using a weight-based heparin dosing protocol for obese and nonobese patients. Am J Health Syst Pharm 2001;58:2143-6.
9. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease. Chest 2008;133:454S-545S. DOI 10.1378/chest.08-0658
10. Estes JW, Pelikan EW, Kruger-Thiemer E. A retrospective study of the pharmacokinetics of heparin. Clin Pharmacol Ther 1969;10:329-37.
11. Estes JW, Poulin PF. Pharmacokinetics of heparin. Distribution and elimination. Thromb Diath Haemorrh 1975; 33:26-37.
12. Chenella FC, Gill MA, Kern JW, Floyd RA, McGehee WG. Improved methods for estimating initial heparin infusion rates. Am J Hosp Pharm 1979;36:782-4.
13. Rosborough TK, Shepherd MF. Achieving target antifactor Xa activity with a heparin protocol based on sex, age, height, and weight. Pharmacotherapy 2004;24:713-9. DOI 10.1592/phco.24.8.713.36067
14. Allen TH, Peng MT, Chen KP, Huang TF, Chang C, Fang HS. Prediction of blood volume and adiposity in man from body weight and cube of height. Metabolism 1956; 5:328-45.
15. Ertl AC, Diedrich A, Satish RR. Techniques used for the determination of blood volume. Am J Med Sci 2007; 334:32-6. DOI 10.1097/MAJ.0b013e318063c6d1
16. Feldshuh J, Enson Y. Prediction of the normal blood volume. Relation of blood volume to body habitus. Circulation 1977;56:605-12.
17. Schwiesow SJ, Wessel AM, Steyer TE. Use of a modified dosing weight for heparin therapy in a morbidly obese patient. Ann Pharmacother 2005;39:753-6. DOI 10.1345/aph.1E300
18. Barletta JF, DeYoung JL, McAllen K, Baker R, Pendleton K. Limitations of a standardized weight-based nomogram for heparin dosing in patients with morbid obesity. Surg Obes Relat Dis 2008;4:748-53. DOI 10.1016/j.soard.2008.03.005
19. Dee BM, Thomas ML. Safety and efficacy of a high-intensity, weight-based, intravenous heparin protocol revision in patients who are obese. Hosp Pharm 2008;43:895-902.
20. Ellison MJ, Sawyer WT, Mills TC. Calculation of heparin dosage in a morbidly obese woman. Clin Pharm 1989;8: 65-8.
21. Holliday DM, Watling SM, Yanos J. Heparin dosing in the morbidly obese patient. Ann Pharmacother 1994;28: 1110-1.
22. World Health Organization. Obesity: preventing and managing the global endemic. WHO Technical Report Series 894. Geneva: World Health Organization, 2000. http://apps.who.int/bmi/ (accessed 2010 Apr 1).
23. Schulman S, Kearon C, for the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3:692-4. DOI 10.1111/j.1538-7836.2005.01204.x
24. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986;315:1109-14.
25. Raschke RA, Gollihare B, Peirce JC. The effectiveness of implementing the weight-based heparin nomogram as a practice guideline. Arch Intern Med 1996;156:1645-9. DOI 10.1001/archinte.156.15.1645
26. Anand SS, Ginsberg JS, Kearon C, Gent M, Hirsh J. The relationship between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin. Arch Intern Med 1996;156:1677-81. DOI 10.1001/archinte.156.15.1677 (Pubitemid 26287124)
27. Anand SS, Bates S, Ginsberg JS, et al. Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin times. Arch Intern Med 1999;159:2029-32. DOI 10.1001/archinte. 159.17.2029
28. Hull RD, Raskob GE, Brant RF, Pineo GF, Valentine KA. Relationship between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. N Engl J Med 1997;157:2562-8.
29. Anand SS, Yusuf S, Pogue J, Ginsberg JS, Hirsh J. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin. Circulation 2003;107:2884-8. DOI 10.1161/01.CIR.0000077530.53367.E9
30. Bauer SR, Ou NN, Dreesman BJ, et al. Effect of body mass index on bleeding frequency and activated partial thromboplastin time in weight-based dosing of unfractionated heparin: a retrospective cohort study. Mayo Clinic Proc 2009;84:1073-8. DOI 10.4065/mcp.2009.0220
31. Lee MS, Wali AU, Menon V, et al. The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIb. J Thromb Thrombolysis 2002;14:91-101. DOI 10.1023/A:1023235926825 (Pubitemid 36559675)
32. Cheng S, Morrow DA, Sloan S, Antman EM, Sabatine MS. Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction. Circulation 2009;119:1195-202. DOI 10.1161/CIRCULATIONAHA.108.814996
33. Hull RD, Raskob GE, Rosenbloom D, et al. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med 1992;152:1589-95. DOI 10.1001/archinte.152.8.1589
34. Badawi O. Possible effect of thyroid function on anticoagulant response to unfractionated heparin. Pharmacotherapy 2006;26:285-8. DOI 10.1592/phco.26.2.285